18. Azaindole Hydroxamic Acids are HIV-1 Integrase Inhibitors

  1. Nouri Neamati
  1. Michael B. Plewe and
  2. Ted W. Johnson

Published Online: 28 SEP 2011

DOI: 10.1002/9781118015377.ch18

HIV-1 Integrase: Mechanism and Inhibitor Design

HIV-1 Integrase: Mechanism and Inhibitor Design

How to Cite

Plewe, M. B. and Johnson, T. W. (2011) Azaindole Hydroxamic Acids are HIV-1 Integrase Inhibitors, in HIV-1 Integrase: Mechanism and Inhibitor Design (ed N. Neamati), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118015377.ch18

Editor Information

  1. Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, California, USA

Author Information

  1. Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA

Publication History

  1. Published Online: 28 SEP 2011
  2. Published Print: 9 SEP 2011

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470184745

Online ISBN: 9781118015377

SEARCH

Keywords:

  • azaindole hydroxamic acids, HIV-1 inhibitors;
  • high-throughput screening;
  • azaindole hydroxamic acid mutagenicity

Summary

This chapter contains sections titled:

  • Introduction

  • High-Throughput Screening

  • Azaindole Hydroxamic Acids

  • β-Carboline Hydroxamic Acids

  • Picoline Hydroxamic Acids

  • Mutagenicity of Azaindole Hydroxamic Acids

  • Metabolic Stability of Azaindole Hydroxamic Acids

  • Synthesis

  • Conclusions

  • Acknowledgments

  • References